The U.S. Food and Drug Administration issued a warning letter to Bayer AG over violations at its drug manufacturing facility in Leverkusen, Germany, Reuters reported.

The German pharmaceutical company is addressing the concerns raised by the regulator.

Bayer is expecting temporary supply limitations that will affect its blood pressure drug Adalat, blood thinner Aspirin Cardio, antibiotic Avelox and potency drug Levitra.

The company will quantify the impact in its upcoming 2018 guidance on Feb. 28.